SG170799A1 - Anti-igf-ir antibodies and uses thereof - Google Patents

Anti-igf-ir antibodies and uses thereof

Info

Publication number
SG170799A1
SG170799A1 SG201102236-5A SG2011022365A SG170799A1 SG 170799 A1 SG170799 A1 SG 170799A1 SG 2011022365 A SG2011022365 A SG 2011022365A SG 170799 A1 SG170799 A1 SG 170799A1
Authority
SG
Singapore
Prior art keywords
igf
antibodies
insulin
fragments
variants
Prior art date
Application number
SG201102236-5A
Other languages
English (en)
Inventor
Kandasamy Hariharan
Christilyn Graff
Scott Glaser
Ellen Garber
Christopher L Reyes
Stephen Demarest
Original Assignee
Biogen Idec Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38656039&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SG170799(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Biogen Idec Inc filed Critical Biogen Idec Inc
Publication of SG170799A1 publication Critical patent/SG170799A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/53—Hinge
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
SG201102236-5A 2006-03-28 2007-03-28 Anti-igf-ir antibodies and uses thereof SG170799A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US78634706P 2006-03-28 2006-03-28
US87655406P 2006-12-22 2006-12-22

Publications (1)

Publication Number Publication Date
SG170799A1 true SG170799A1 (en) 2011-05-30

Family

ID=38656039

Family Applications (1)

Application Number Title Priority Date Filing Date
SG201102236-5A SG170799A1 (en) 2006-03-28 2007-03-28 Anti-igf-ir antibodies and uses thereof

Country Status (13)

Country Link
US (3) US7612178B2 (de)
EP (1) EP1999149A4 (de)
JP (1) JP2009532027A (de)
KR (1) KR20080113268A (de)
AU (1) AU2007245164A1 (de)
BR (1) BRPI0709843A2 (de)
CA (1) CA2646406A1 (de)
EA (1) EA200802061A1 (de)
IL (1) IL194266A0 (de)
MX (1) MX2008012146A (de)
NO (1) NO20084521L (de)
SG (1) SG170799A1 (de)
WO (1) WO2007126876A2 (de)

Families Citing this family (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080152649A1 (en) * 2002-03-01 2008-06-26 Xencor, Inc. Optimized igf-1r antibodies and methods of using the same
US8168181B2 (en) 2006-02-13 2012-05-01 Alethia Biotherapeutics, Inc. Methods of impairing osteoclast differentiation using antibodies that bind siglec-15
CA2638823A1 (en) 2006-02-13 2007-08-23 Alethia Biotherapeutics Inc. Polynucleotides and polypeptide sequences involved in the process of bone remodeling
US7612178B2 (en) 2006-03-28 2009-11-03 Biogen Idec Ma Inc Anti-IGF-1R antibodies and uses thereof
EP2006381B1 (de) 2006-03-31 2016-02-03 Chugai Seiyaku Kabushiki Kaisha Verfahren zur kontrolle der blut-pharmakokinetik von antikörpern
US7846724B2 (en) 2006-04-11 2010-12-07 Hoffmann-La Roche Inc. Method for selecting CHO cell for production of glycosylated antibodies
CL2007002502A1 (es) * 2006-08-31 2008-05-30 Hoffmann La Roche Variantes del factor de crecimiento similar a insulina-1 humano (igf-1) pegilados en lisina; metodo de produccion; proteina de fusion que la comprende; y su uso para tratar la enfermedad de alzheimer.
GB0702888D0 (en) * 2007-02-14 2007-03-28 Glaxo Group Ltd Novel Antibodies
PE20090368A1 (es) 2007-06-19 2009-04-28 Boehringer Ingelheim Int Anticuerpos anti-igf
EP2193148A2 (de) * 2007-07-27 2010-06-09 Facet Biotech Corporation Einen tyrosinkinaseinhibitor und einen antikörper gegen integrin alpha 1 beta 5 (cd49e) enthaltende pharmazeutische kombination
JP2010538012A (ja) * 2007-08-28 2010-12-09 バイオジェン アイデック マサチューセッツ インコーポレイテッド Ｉｇｆ−１ｒの複数のエピトープに結合する組成物
JP2010537985A (ja) * 2007-08-28 2010-12-09 バイオジェン アイデック マサチューセッツ インコーポレイテッド 抗ｉｇｆ−１ｒ抗体およびその使用
PL2202245T3 (pl) 2007-09-26 2017-02-28 Chugai Seiyaku Kabushiki Kaisha Sposób modyfikowania punktu izoelektrycznego przeciwciała poprzez podstawienie aminokwasu w cdr
CA2694154A1 (en) * 2007-10-03 2009-04-09 Osi Pharmaceuticals, Inc. Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors
WO2009045389A2 (en) * 2007-10-03 2009-04-09 Osi Pharmaceuticals, Inc. Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors
BRPI0821417A2 (pt) * 2007-12-26 2015-06-16 Biotest Ag Método para diminuir a adesão de células de estroma a células tumorais que expressam cd138 em células tumorais de um indivíduo em necessidade do mesmo
RU2547939C2 (ru) * 2007-12-26 2015-04-10 Биотест Аг Иммуноконъюгаты, направленные на cd138, и их применение
WO2009120993A2 (en) * 2008-03-28 2009-10-01 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Synthetic analogs of the juxtamembrane domain of igf1r and uses thereof
ES2563483T3 (es) 2008-04-11 2016-03-15 Chugai Seiyaku Kabushiki Kaisha Molécula de unión a antígeno capaz de unirse repetidamente a dos o más moléculas de antígeno
US20090291088A1 (en) * 2008-04-11 2009-11-26 Biogen Idec Ma Inc. Therapeutic combinations of anti-igf-1r antibodies and other compounds
EP2282769A4 (de) 2008-04-29 2012-04-25 Abbott Lab Dual-variable- domain-immunglobuline und ihre verwendungen
CA2726087A1 (en) 2008-06-03 2009-12-10 Tariq Ghayur Dual variable domain immunoglobulins and uses thereof
JP2012508563A (ja) * 2008-11-12 2012-04-12 シェーリング コーポレイション 抗ＩＧＦ１Ｒ発現の増強のためのβＧｌ−ＩＧＧイントロン
BRPI0923359B8 (pt) 2008-12-12 2021-05-25 Boehringer Ingelheim Int molécula de anticorpo anti-igf, método para a produção da mesma, molécula de dna, vetor de expressão, e composição farmacêutica e método in vitro para inibir a ligação do igf-1 e do igf-2 ao receptor de igf-1 e ao receptor de insulina ir-a
CA2748119A1 (en) * 2008-12-23 2010-07-01 Salk Institute For Biological Studies Method of treating neurodegenerative disease
EP2400990A2 (de) * 2009-02-26 2012-01-04 OSI Pharmaceuticals, LLC In-situ-verfahren zur überwachung des emt-status von tumorzellen in vivo
US20100316639A1 (en) 2009-06-16 2010-12-16 Genentech, Inc. Biomarkers for igf-1r inhibitor therapy
US8926976B2 (en) * 2009-09-25 2015-01-06 Xoma Technology Ltd. Modulators
JP5711751B2 (ja) 2009-10-26 2015-05-07 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ グリコシル化された免疫グロブリンの調製方法
WO2011083391A2 (en) 2010-01-05 2011-07-14 Pfizer Inc. Biomarkers for anti-igf-ir cancer therapy
EP2525820B1 (de) * 2010-01-19 2016-05-11 Immunomedics, Inc. Neue klasse monospezifischer und bispezifischer humanisierter antikörper zur anzielung des insulinähnlichen wachstumsfaktorrezeptors vom typ 1 (igf-1r)
EP2542893A2 (de) * 2010-03-03 2013-01-09 OSI Pharmaceuticals, LLC Biologische marker als prädiktoren der antikrebsreaktion auf insulinähnlichen wachstumsfaktor-1-rezeptor-kinaseinhibitoren
WO2011161119A1 (en) * 2010-06-22 2011-12-29 F. Hoffmann-La Roche Ag Antibodies against insulin-like growth factor i receptor and uses thereof
UY33492A (es) 2010-07-09 2012-01-31 Abbott Lab Inmunoglobulinas con dominio variable dual y usos de las mismas
CN103298834A (zh) 2010-08-03 2013-09-11 Abbvie公司 双重可变结构域免疫球蛋白及其用途
DE102010035003B4 (de) * 2010-08-20 2015-08-06 PicoQuant GmbH. Unternehmen für optoelektronische Forschung und Entwicklung Räumlich und zeitlich hochauflösende Mikroskopie
US20140234340A1 (en) 2010-11-30 2014-08-21 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule capable of binding to plurality of antigen molecules repeatedly
JP2014510265A (ja) 2011-02-02 2014-04-24 アムジェン インコーポレイテッド Ｉｇｆ−１ｒの阻害に関する方法および組成物
WO2012149014A1 (en) 2011-04-25 2012-11-01 OSI Pharmaceuticals, LLC Use of emt gene signatures in cancer drug discovery, diagnostics, and treatment
AU2012335541B2 (en) 2011-11-11 2017-07-06 Duke University Combination drug therapy for the treatment of solid tumors
RU2632108C2 (ru) 2011-12-08 2017-10-02 Биотест Аг Применения иммуноконъюгатов, мишенью которых является cd138
SG11201402828XA (en) * 2011-12-22 2014-10-30 Rinat Neuroscience Corp Human growth hormone receptor antagonist antibodies and methods of use thereof
WO2013191982A2 (en) * 2012-06-21 2013-12-27 Sorrento Therapeutics Inc. Antigen binding proteins that bind igf1r
CA2928851A1 (en) 2012-07-19 2014-01-23 Alethia Biotherapeutics Inc. Anti-siglec-15 antibodies
US8980259B2 (en) 2012-07-20 2015-03-17 Novartis Ag Combination therapy
CA2882272C (en) 2012-08-24 2023-08-29 Chugai Seiyaku Kabushiki Kaisha Fc.gamma.riib-specific fc region variant
WO2014030750A1 (ja) 2012-08-24 2014-02-27 中外製薬株式会社 マウスFcγRII特異的Fc抗体
WO2014107165A1 (en) * 2013-01-05 2014-07-10 R-PHARM, CJSC (Closed Joint Stock Company) Fully human antibodies against human receptor igf-1r
US20140255413A1 (en) 2013-03-07 2014-09-11 Boehringer Ingelheim International Gmbh Combination therapy for neoplasia treatment
EP2982689B1 (de) 2013-04-02 2020-08-26 Chugai Seiyaku Kabushiki Kaisha Varianten der fc-region
KR101895634B1 (ko) * 2013-05-31 2018-09-05 한미약품 주식회사 변이된 힌지 영역을 포함하는 IgG4 Fc 단편
LT3134438T (lt) * 2014-04-25 2021-01-11 Pierre Fabre Médicament Igf-1r antikūnas ir jo panaudojimas kaip nukreipiančio nešiklio, skirtas vėžio gydymui
SG11201700841QA (en) 2014-12-19 2017-03-30 Chugai Pharmaceutical Co Ltd Anti-myostatin antibodies, polypeptides containing variant fc regions, and methods of use
CN107108729A (zh) 2015-02-05 2017-08-29 中外制药株式会社 包含离子浓度依赖性的抗原结合结构域的抗体，fc区变体，il‑8‑结合抗体，及其应用
AR104413A1 (es) * 2015-04-27 2017-07-19 Pf Medicament Anticuerpo de igf-1r y su utilización para diagnosticar cáncer
TWI716400B (zh) * 2015-04-27 2021-01-21 法商皮爾法伯製藥公司 新穎的igf-1r抗體及其用於癌症診斷之用途（二）
JP7141336B2 (ja) 2015-12-25 2022-09-22 中外製薬株式会社 抗ミオスタチン抗体および使用方法
CA3026050A1 (en) 2016-08-05 2018-02-08 Chugai Seiyaku Kabushiki Kaisha Composition for prophylaxis or treatment of il-8 related diseases
SG10201607778XA (en) 2016-09-16 2018-04-27 Chugai Pharmaceutical Co Ltd Anti-Dengue Virus Antibodies, Polypeptides Containing Variant Fc Regions, And Methods Of Use
US20200276273A1 (en) * 2017-09-21 2020-09-03 University Of Miami Method for treating myeloid leukemia
CA3093729A1 (en) 2018-03-15 2019-09-19 Chugai Seiyaku Kabushiki Kaisha Anti-dengue virus antibodies having cross-reactivity to zika virus and methods of use
US11446401B2 (en) * 2018-12-03 2022-09-20 Fusion Pharmaceuticals Inc. Actinium-225 and checkpoint inhibitor combination therapy
CN114874333A (zh) * 2021-10-18 2022-08-09 深圳科兴药业有限公司 一种生长激素融合蛋白及其应用
CN117347626B (zh) * 2023-12-06 2024-03-12 安徽惠邦生物工程有限公司 人胰岛素样生长因子结合蛋白-1化学发光免疫分析试剂盒及其制备方法

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5859205A (en) * 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
US5587458A (en) * 1991-10-07 1996-12-24 Aronex Pharmaceuticals, Inc. Anti-erbB-2 antibodies, combinations thereof, and therapeutic and diagnostic uses thereof
DE69332859T2 (de) * 1992-11-13 2003-12-18 Idec Pharmaceuticals Corp., San Diego Konsensus-kozak-sequenzen zur säugetier-exprimierung
AU5670194A (en) * 1992-11-20 1994-06-22 Enzon, Inc. Linker for linked fusion polypeptides
US6262238B1 (en) * 1997-01-14 2001-07-17 Roche Diagnostic, Gmbh Process for modifying the stability of antibodies
CA2369622C (en) 1999-04-09 2011-06-14 Universitat Zurich Novel method for the stabilization of chimeric immunoglobulins or immunoglobulin fragments, and stabilized anti-egp-2 scfv fragment
US20020103345A1 (en) 2000-05-24 2002-08-01 Zhenping Zhu Bispecific immunoglobulin-like antigen binding proteins and method of production
US7858559B2 (en) * 2000-11-17 2010-12-28 University Of Rochester In vitro methods of producing and identifying immunoglobulin molecules in eukaryotic cells
EP2275446A3 (de) * 2001-01-05 2012-08-15 Pfizer Inc. Antikörper für Insulinwachstumsfaktor-1-Rezeptor
US7553485B2 (en) * 2002-01-18 2009-06-30 Pierre Fabre Medicament Anti-IGF-IR and/or anti-insulin/IGF-I hybrid receptors antibodies and uses thereof
KR101086533B1 (ko) * 2002-05-24 2011-11-23 쉐링 코포레이션 중화 사람 항-ｉｇｆｒ 항체, 이를 제조하는 방법 및 이를 포함하는 조성물
US8034904B2 (en) * 2002-06-14 2011-10-11 Immunogen Inc. Anti-IGF-I receptor antibody
CA2518980A1 (en) * 2003-03-14 2004-09-30 Pharmacia Corporation Antibodies to igf-i receptor for the treatment of cancers
ATE549359T1 (de) * 2003-04-02 2012-03-15 Hoffmann La Roche Antikörper gegen den insulinähnlichen wachstumsfaktor i-rezeptor und deren verwendungen
US7638605B2 (en) * 2003-05-01 2009-12-29 ImClone, LLC Fully human antibodies directed against the human insulin-like growth factor-1 receptor
US7579157B2 (en) * 2003-07-10 2009-08-25 Hoffmann-La Roche Inc. Antibody selection method against IGF-IR
WO2005058967A2 (en) * 2003-12-16 2005-06-30 Pierre Fabre Medicament Novel anti-insulin/igf-i hybrid receptor or anti-insulin/igf-i hybrid receptor and igf-ir antibodies and uses thereof
CN1961071A (zh) 2004-03-15 2007-05-09 比奥根艾迪克Ma公司 使用可选剪接在真核细胞中表达多肽多聚体的方法和构建物
EP1755660B1 (de) * 2004-05-07 2010-03-24 The University of North Carolina at Chapel Hill Verfahren zur verstärkung oder hemmung des insulinähnlichen wachstumsfaktors-i
WO2006020706A2 (en) * 2004-08-12 2006-02-23 Dyax Corp. Tie complex binding proteins
MY146381A (en) 2004-12-22 2012-08-15 Amgen Inc Compositions and methods relating relating to anti-igf-1 receptor antibodies
WO2006074399A2 (en) 2005-01-05 2006-07-13 Biogen Idec Ma Inc. Multispecific binding molecules comprising connecting peptides
US20090030187A1 (en) * 2005-03-14 2009-01-29 Tous Guillermo I Macromolecules comprising a thioether cross-link
FR2888850B1 (fr) 2005-07-22 2013-01-11 Pf Medicament Nouveaux anticorps anti-igf-ir et leurs applications
US7612178B2 (en) 2006-03-28 2009-11-03 Biogen Idec Ma Inc Anti-IGF-1R antibodies and uses thereof
JP2010538012A (ja) * 2007-08-28 2010-12-09 バイオジェン アイデック マサチューセッツ インコーポレイテッド Ｉｇｆ−１ｒの複数のエピトープに結合する組成物
JP2010537985A (ja) * 2007-08-28 2010-12-09 バイオジェン アイデック マサチューセッツ インコーポレイテッド 抗ｉｇｆ−１ｒ抗体およびその使用
US20090291088A1 (en) * 2008-04-11 2009-11-26 Biogen Idec Ma Inc. Therapeutic combinations of anti-igf-1r antibodies and other compounds

Also Published As

Publication number Publication date
IL194266A0 (en) 2011-08-01
US8147829B2 (en) 2012-04-03
US20100098710A1 (en) 2010-04-22
KR20080113268A (ko) 2008-12-29
NO20084521L (no) 2008-12-23
EP1999149A4 (de) 2010-01-20
US20100099147A1 (en) 2010-04-22
US20070243194A1 (en) 2007-10-18
JP2009532027A (ja) 2009-09-10
CA2646406A1 (en) 2007-11-08
MX2008012146A (es) 2008-10-03
EP1999149A2 (de) 2008-12-10
WO2007126876A3 (en) 2008-04-03
EA200802061A1 (ru) 2009-04-28
BRPI0709843A2 (pt) 2011-07-26
AU2007245164A1 (en) 2007-11-08
WO2007126876A2 (en) 2007-11-08
US7612178B2 (en) 2009-11-03

Similar Documents

Publication Publication Date Title
SG170799A1 (en) Anti-igf-ir antibodies and uses thereof
MX2010008025A (es) Anticuerpos ron y usos de los mismos.
WO2003059951A3 (fr) Anticorps anti-igf-ir et leurs applications
EP2190480A4 (de) Anti-igr-1r-antikörper und ihre verwendungen
TW200740846A (en) Novel anti-IGF-IR antibodies and uses thereof
TW200628490A (en) Novel anti-IGF-IR antibodies and uses thereof
WO2004043344A3 (en) Anti-cd33 antibodies and method for treatment of acute myeloid leukemia using the same
EP2100614A3 (de) PDGFR-alpha Antagonisten zur Behandlung von metastasierendem Knochenkarzinom
WO2005058967A3 (en) Novel anti-insulin/igf-i hybrid receptor or anti-insulin/igf-i hybrid receptor and igf-ir antibodies and uses thereof
WO2006087637A3 (en) Anti her2/neu antibody
WO2005077091A8 (en) Nicotinamide riboside kinase compositions and methods for using the same
GEP20166454B (en) Sclerostin binding agents
RS20150135A1 (en) TREATMENT WITH ANTI-VEGF ANTIBODIES
DE60028970D1 (de) An her2 bindende peptidverbindungen
WO2005080431A3 (en) Monoclonal antibodies that specifically bind to folate receptor alpha
WO2004009622A3 (en) Protein complexes of cellular networks underlying the development of cancer and other diseases
MXPA05012832A (es) Punto terminal terapeutico sustituto para inmunoterapia de enfermedad basada en anti-ctla-4.
WO2007015935A8 (en) Diagnostic methods for the prediction of therapeutic success, recurrence free and overall survival in cancer therapy
WO2007033167A3 (en) Compositions and methods for detecting and treating cancer
MXPA05011085A (es) Composiciones y metodos relacionados a stop-1.
MXPA05007940A (es) Composiciones y metodos para el tratamiento del cancer usando igsf9 y liv-1.
MXPA03005030A (es) Juego de reactivos inmunoterapeuticos para el tratamiento de tumores.
IL207012A0 (en) Diagnosis and therapy of cancer using sgp28-related molecules
MXPA01010186A (es) Composiciones y metodos para el tratamiento y diagnostico de cancer de mama.
SG148035A1 (en) Gene products differentially expressed in cancerous breast cells and their methods of use